Clinical Trial Update: ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 study of ALRN-6924 in patients with advanced solid tumors and lymphomas have been posted after completion of the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Peripheral T-cell Lymphoma
• Solid Tumor

Drugs mentioned

• ALRN-6924 (MDM2/MDMX dual inhibitor)

Snippet

Sponsor: Aileron Therapeutics, Inc. | Conditions: Solid Tumor, Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-01-13